• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Sunovion, medical society ally for COPD drug-delivery survey

October 21, 2016 By Sarah Faulkner

Sunovion, American College of Chest PhysiciansSunovion Pharmaceuticals and the American College of Chest Physicians yesterday launched a strategic initiative called Delivery Makes a Difference to better understand patient and healthcare provider practices in COPD therapy.

A series of “nationally recognized COPD thought leaders” came together to be a part of the steering committee for the initiative. They developed a survey for 1,000 patients and providers to assess drug-device prescription habits. The team also hopes to gain insight into perception disparities between patients and healthcare providers.

The survey results will be used to create educational materials for providers to use when making decisions about a patient’s individual treatment regimen.

“When 1st-line treatments fail to achieve their desired effect, healthcare providers often prescribe additional medications, failing to consider that the way the medicine has been delivered may be a significant issue,” Dr. Nicola Hanania, chair of the Delivery Makes a Difference steering committee, said in prepared remarks. “The Delivery Makes a Difference initiative hopes to provide important data to support the crucial step of choosing appropriate delivery devices for individual patients.”

“The American College of Chest Physicians believes that a comprehensive approach to the patient’s needs is essential to optimal treatment of COPD,” added Dr. John Alexander, president of CHEST Enterprises. “Great patient care extends beyond the molecule, considering patient ability, delivery systems and ongoing doctor/patient communication.”

“Sunovion is proud to be working with CHEST to facilitate this important discussion with health care providers and patients about the role of delivery devices for COPD medications,” Sunovion executive VP & chief medical officer Dr. Antony Loebel said. “We look forward to sharing the data from this survey with health care providers and to providing meaningful educational programs for patients.”

Filed Under: Drug-Device Combinations, Featured, Respiratory Tagged With: American College of Chest Physicians, Sunovion Pharmaceuticals

IN CASE YOU MISSED IT

  • Breakthrough T1D, Mattel debut Barbie doll with type 1 diabetes
  • Medtronic Diabetes names CFO with consumer experience ahead of separation
  • Diabeloop launches insulin delivery algorithm in Germany
  • GlucoModicum has positive data for needle-free CGM
  • Lifecare takes next steps in CGM implant development

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS